Immunology and inflammation biotech company Bambusa (BBTX.US) prices IPO at $15-17 per share, aims to raise $150 million.

According to Golden Ten Data, Bambusa Therapeutics, a biotechnology company focused on immunology and inflammation, announced on Monday the terms for its initial public offering (IPO). The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Based on the midpoint of the proposed pricing range, Bambusa Therapeutics’ fully diluted market capitalization will reach $837 million. The company plans to list on Nasdaq under the ticker symbol “BBTX.” The IPO is expected to be priced during the week of October 26, 2026.

Headquartered in Boston, Massachusetts, USA, Bambusa Therapeutics is a clinical-stage biotechnology company developing long-acting bispecific antibodies for immunology and inflammatory diseases. Its core drug candidate, BBT001, targets IL-4Rα and IL-31, is currently undergoing a Phase I trial for atopic dermatitis, with initial proof-of-concept data released in July 2026; in addition, the drug is also in a Phase IIa trial in China for chronic spontaneous urticaria.

The company’s second candidate, BBT002, targets IL-4Rα and IL-5, and is currently in Phase I to IIa trials for chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and asthma.

In addition, the company has two preclinical projects: BBT003, which targets TL1A and IL-23p19 for the treatment of inflammatory bowel disease; and BBT004, a bispecific antibody designed to deplete B cells for the treatment of autoimmune diseases. All of Bambusa Therapeutics' core assets are licensed from the Chinese subsidiary of the German biotechnology company BioNTech.